Skip to main content

Table 1 Characteristics of included studies comparing S + IORT+EBRT+CHT versus S + EBRT+CHT

From: The role of intraoperative radiation therapy in resectable pancreatic cancer: a systematic review and meta-analysis

Study

Nation

Study design

Study period

Sample size, n

Mean age (year)

Male, %

CHT, n

EBRT, n

Tumor Size

(mean, cm)

Median Survival Time

(month)

Tumor Staging, n

(+) vs. (−)

Study quality

(+)

(−)

(+)

(−)

(+)

(−)

(+)

(−)

(+)

(−)

(+)

(−)

(+)

(−)

Dobelbower-1 1997 [14]

USA

R

1980–1995

10

14

58.4

60.5

54.5%a

9

9

10

14

4.8

3.3

17.5

14.5

Stage I: 1 vs. 4

Stage II: 4 vs, 6

Stage III: 6 vs. 4

*******

Nishimura 1997 [28]

Japan

R

1980–1995

32

24

62a

NA

NA

6

2

19

24

NA

NA

15.5

13.0

Stage I: 13% vs. 8%

Stage II: 13% vs. 29%

Stage III: 48% vs. 39%

Stage IV: 28% vs. 24%

******

Reni 2001 [10]

Italy

R

1985–1998

127

76

61.8

62.3

52

63.2

56

26

41

15

3.2

3.5

14.5

12.0

Stage I: 5 vs. 4

Stage II: 25 vs, 15

Stage III: 55 vs. 35

Stage IV: 42 vs. 22

*******

Showalter 2009 [25]

USA

PCD

1995–2005

37

46

64

67

NA

NA

26

27

23

29

NA

NA

19.2

21.0

Stage I: 7 vs. 16

Stage IIA: 6 vs. 12

Stage ≥IIB: 24 vs. 18

******

Calvo 2013 [22]

Spain

PCD

1995–2012

29

31

60

62

58.6

64.5

18

19

29

31

NA

NA

NA

NA

Stage IB-IIA:

13 vs. 16

Stage IIB-III:

16 vs. 15

*******

Keane 2018 [29]

USA

R

2010-

2015

22

19

63a

37a

22

19

22

19

3.6a

35.1

24.5

41 underwent resection (no evidence of distant metastases after NAT)

*******

  1. S indicates surgery, IORT intraoperative radiotherapy, EBRT external beam radiotherapy, CHT chemotherapy, NAT neoadjuvant treatment
  2. PCD prospectively collected data, R retrospective case-matched study
  3. aThe Whole study; (+), IORT group; (−), Non-IORT group; NA no available; *represented one point, a score of 0 to 9 was assigned to each study and studies achieving a score of 6 or greater were considered high quality